Endologix Inc (ELGX):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Endologix Inc (ELGX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7516
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Endologix, Inc. (Endologix) is a medical device company. It undertakes the development, manufacturing and selling of minimally invasive treatments for aortic diseases. The company lays focus on its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). The company’s AAA products are built on traditional minimally-invasive endovascular repair (EVAR) platform or endovascular sealing (EVAS) platform. The company’s EVAR products include AFX endovascular AAA system Vela Proximal Endograft and Intuitrak endovascular AAA system; and EVAS products comprise Nellix endovascular aneurysm sealing system. It has manufacturing facility in Irvine. The company sells its products to hospitals in the US and Europe through direct sales force and through third-party international distributors and agents in other parts of the world. Endologix is headquartered in California, the US.

Endologix Inc (ELGX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Endologix Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Endologix Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Endologix Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Endologix Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Endologix Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Endologix Inc, Medical Equipment, Deal Details 12
Venture Financing 12
TriVascular Raises US$2 Million In Venture Financing 12
TriVascular Raises US$40 Million In Series E Financing 13
TV2 Raises US$0.07 Million In Venture Financing 15
Trivascular Raises Funds Through Initial Tranche Of Series D Financing 16
TriVascular Raises US$7.2 Million In Venture Financing 18
Partnerships 19
Endologix Enters into Co-Development Agreement with Japan Lifeline 19
Equity Offering 20
Endologix Plans to Raise Funds through Public Offering of Shares 20
Endologix Raises USD210 Million in Private Placement 21
Endologix Plans to Raise USD100 Million in Public Offering of Securities 22
Endologix Plans to Raise USD46.2 Million in Equity Offering of Shares 23
TriVascular Technologies Completes IPO For US$89.7 Million 24
Endologix Completes Public Offering Of Common Stock For US$40 Million 26
Debt Offering 27
Endologix Raises USD125 Million in Public Offering of 3.25% Notes Due 2020 27
TriVascular Raises USD10 Million in Private Placement 29
Endologix Completes Public Offering Of Notes Due 2018 For US$86.3 Million 30
Acquisition 32
Endologix Acquires TriVascular Technologies 32
Endologix Inc – Key Competitors 34
Endologix Inc – Key Employees 35
Endologix Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Oct 02, 2018: Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range 37
Aug 09, 2018: Endologix reports second quarter 2018 financial results 38
May 02, 2018: Endologix Announces First Quarter 2018 Financial Results 39
Feb 21, 2018: Endologix Reports Fourth Quarter and Fiscal Year 2017 Financial Results 40
Nov 07, 2017: Endologix Reports Third Quarter 2017 Financial Results 42
Aug 02, 2017: Endologix Reports Second Quarter 2017 Financial Results 43
May 04, 2017: Endologix Reports First Quarter 2017 Financial Results 44
Feb 22, 2017: Endologix Reports Results for the Fourth Quarter and Full Year 2016 45
Corporate Communications 47
Aug 15, 2018: Endologix appoints Jeffrey S. Brown as Chief Operations Officer 47
Jun 25, 2018: Endologix Names Jeffry Fecho As Chief Quality Officer 48
May 02, 2018: Endologix Names John Onopchenko As Chief Executive Officer 49
Feb 21, 2018: Endologix Announces Resignation Of John McDermott As Chief Executive Officer 50
Jan 29, 2018: Endologix Names Greg Morrow As Chief Marketing Officer 51
Jan 29, 2018: Endologix Appoints Greg Morrow as Chief Marketing Officer 52
Oct 19, 2017: Endologix Appoints John Onopchenko as Chief Operating Officer 53
Feb 06, 2017: Endologix Announces Appointment of Dan Lemaitre as Chairman of the Board 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Endologix Inc, Medical Equipment, Key Facts, 2017 2
Endologix Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Endologix Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Endologix Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Endologix Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Endologix Inc, Deals By Market, 2012 to YTD 2018 9
Endologix Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
TriVascular Raises US$2 Million In Venture Financing 12
TriVascular Raises US$40 Million In Series E Financing 13
TV2 Raises US$0.07 Million In Venture Financing 15
Trivascular Raises Funds Through Initial Tranche Of Series D Financing 16
TriVascular Raises US$7.2 Million In Venture Financing 18
Endologix Enters into Co-Development Agreement with Japan Lifeline 19
Endologix Plans to Raise Funds through Public Offering of Shares 20
Endologix Raises USD210 Million in Private Placement 21
Endologix Plans to Raise USD100 Million in Public Offering of Securities 22
Endologix Plans to Raise USD46.2 Million in Equity Offering of Shares 23
TriVascular Technologies Completes IPO For US$89.7 Million 24
Endologix Completes Public Offering Of Common Stock For US$40 Million 26
Endologix Raises USD125 Million in Public Offering of 3.25% Notes Due 2020 27
TriVascular Raises USD10 Million in Private Placement 29
Endologix Completes Public Offering Of Notes Due 2018 For US$86.3 Million 30
Endologix Acquires TriVascular Technologies 32
Endologix Inc, Key Competitors 34
Endologix Inc, Key Employees 35
Endologix Inc, Subsidiaries 36

List of Figures
Endologix Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Endologix Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Endologix Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Endologix Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Endologix Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Endologix Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Endologix Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Endologix Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Endologix Inc (ELGX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Electricity Generating Authority of Thailand:電力:M&Aディール及び事業提携情報
    Summary Electricity Generating Authority of Thailand (EGAT) is a state-owned power utility. It generates, procures, transmits, and distributes electricity. The authority produces energy using hydro, coal, natural gas, diesel, fuel oil and palm oil, and renewable sources. EGAT procures electricity fr …
  • RespireRx Pharmaceuticals Inc (RSPI):製薬・医療:M&Aディール及び事業提携情報
    Summary RespireRx Pharmaceuticals Inc (RespireRx), formerly Cortex Pharmaceuticals, Inc., focuses on the discovery, development and commercialization of innovative products for the treatment of various respiratory disorders. It has two drug platforms, each with a clinical stage compound directed at …
  • GE Aviation:企業の戦略・SWOT・財務情報
    GE Aviation - Strategy, SWOT and Corporate Finance Report Summary GE Aviation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Imperial Metals Corporation:企業の戦略・SWOT・財務情報
    Imperial Metals Corporation - Strategy, SWOT and Corporate Finance Report Summary Imperial Metals Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • PQ Group Holdings Inc (PQG):企業の財務・戦略的SWOT分析
    PQ Group Holdings Inc (PQG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Investment Technology Group, Inc.
    Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Valid Solucoes SA (VLID3):企業の財務・戦略的SWOT分析
    Valid Solucoes SA (VLID3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tec-Masters Inc:企業の戦略・SWOT・財務情報
    Tec-Masters Inc - Strategy, SWOT and Corporate Finance Report Summary Tec-Masters Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Minesto AB (MINEST):電力:M&Aディール及び事業提携情報
    Summary Minesto AB (Minesto) is a marine energy technology developer. The company offers ervices such as renewable energy solutions, tidal power plants operations and management, power generation, and deep green technology solutions. It also provides control-system design, hydrodynamics, simulation, …
  • Molecular Partners AG (MOLN):企業の財務・戦略的SWOT分析
    Summary Molecular Partners AG (Molecular Partners) is a clinical stage bio pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for diabetic macular edema an …
  • Pets at Home Group Plc.:企業の戦略・SWOT・財務分析
    Pets at Home Group Plc. - Strategy, SWOT and Corporate Finance Report Summary Pets at Home Group Plc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Henry Lamotte Group:企業の戦略・SWOT・財務情報
    Henry Lamotte Group - Strategy, SWOT and Corporate Finance Report Summary Henry Lamotte Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • PT Soho Global Health Tbk (SOHO):企業の財務・戦略的SWOT分析
    PT Soho Global Health Tbk (SOHO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Brasfield & Gorrie LLC:企業の戦略・SWOT・財務情報
    Brasfield & Gorrie LLC - Strategy, SWOT and Corporate Finance Report Summary Brasfield & Gorrie LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Karnataka Power Corporation Ltd:企業の戦略的SWOT分析
    Karnataka Power Corporation Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Tokio Marine & Nichido Fire Insurance Co., Ltd.:企業のM&A・事業提携・投資動向
    Tokio Marine & Nichido Fire Insurance Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tokio Marine & Nichido Fire Insurance Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business descript …
  • American Electric Power Company, Inc.:企業の戦略・SWOT・財務分析
    American Electric Power Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary American Electric Power Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Bayer AG (BAYN)-製薬・医療分野:企業M&A・提携分析
    Summary Bayer AG (Bayer) carries out the research, development, production and commercialization of products in the areas of human and animal health care, and agriculture. It provides pharmaceuticals for cardiology, women’s healthcare, oncology, hematology, ophthalmology, infection and other indicat …
  • SBS Transit Ltd.:企業の戦略・SWOT・財務情報
    SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report Summary SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Prysmian S.p.A.:企業のM&A・事業提携・投資動向
    Prysmian S.p.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Prysmian S.p.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆